<DOC>
	<DOCNO>NCT01868542</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial compare glycaemic control Levemir® ( insulin detemir ) administer daily accord two titration algorithms 20 week subject type 2 diabetes inadequately control metformin treatment without anti-diabetic drug ( OADs ) .</brief_summary>
	<brief_title>A Trial Comparing Glycaemic Control Levemir® Administered Once Daily According Two Insulin Detemir Titration Algorithms After 20 Weeks Subjects With Type 2 Diabetes Mellitus Inadequately Controlled Metformin Treatment With Without Other Anti-diabetic Drugs ( OADs )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Diagnosed type 2 diabetes mellitus least 3 month prior Visit 1 ( week 2 ) Treatment least 1000 mg metformin per day with/without OADs stable dose ( either maximal tolerate dose least half maximum recommend dose accord package insert ) least 3 month prior Visit 1 Insulinnaïve subject HbA1c equal 7.5 % central laboratory analysis Body mass index ( BMI ) equal 35.0 kg/m^2 Female breastfeed The receipt investigational product within 4 week prior Visit 1 Any contraindication insulin detemir accord domestic labelling Anticipated change dose systemic treatment product , investigator 's opinion could interfere glucose metabolism ( systemic corticosteroid , betablockers , monoamine oxidase [ MAO ] inhibitor ) Clinically significant disease , investigator 's opinion , may confound result trial pose additional risk administer trial product Any condition investigator judge would interfere trial participation evaluation result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>